Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its lead asset ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases.
|30 Jul 2021||$0.29||$-0.01||-3.33%||243,924||$0.30||$0.30||$0.28|
|29 Jul 2021||$0.30||$0.00||0.00%||77,405||$0.31||$0.31||$0.30|
|28 Jul 2021||$0.30||$-0.01||-3.28%||82,144||$0.31||$0.31||$0.30|
|27 Jul 2021||$0.31||$-0.02||-6.25%||365,761||$0.32||$0.32||$0.30|
|26 Jul 2021||$0.32||$0.01||3.23%||250,455||$0.32||$0.33||$0.32|
|23 Jul 2021||$0.31||$-0.01||-3.17%||139,717||$0.32||$0.32||$0.31|
|22 Jul 2021||$0.32||$0.02||6.78%||561,503||$0.31||$0.33||$0.30|
|21 Jul 2021||$0.30||$-0.02||-6.45%||645,279||$0.31||$0.31||$0.30|
|20 Jul 2021||$0.31||$-0.02||-6.06%||426,158||$0.32||$0.32||$0.31|
|19 Jul 2021||$0.33||$-0.01||-2.94%||194,119||$0.34||$0.34||$0.33|
|16 Jul 2021||$0.34||$0.02||6.15%||396,649||$0.32||$0.37||$0.31|
|15 Jul 2021||$0.33||$0.00||0.00%||89,166||$0.35||$0.35||$0.33|
|14 Jul 2021||$0.33||$-0.03||-8.57%||84,110||$0.36||$0.36||$0.33|
|13 Jul 2021||$0.35||$0.02||6.06%||340,046||$0.33||$0.35||$0.33|
|12 Jul 2021||$0.33||$0.00||0.00%||182,915||$0.33||$0.34||$0.33|
|09 Jul 2021||$0.33||$0.02||6.35%||690,041||$0.31||$0.35||$0.31|
|08 Jul 2021||$0.32||$0.02||6.67%||76,401||$0.31||$0.32||$0.31|
|07 Jul 2021||$0.30||$0.02||7.02%||526,922||$0.29||$0.31||$0.29|
|06 Jul 2021||$0.29||$-0.01||-3.45%||334,804||$0.31||$0.31||$0.29|
|05 Jul 2021||$0.29||$0.01||3.57%||371,532||$0.28||$0.29||$0.28|
|02 Jul 2021||$0.28||$-0.03||-9.84%||218,836||$0.30||$0.30||$0.28|
|Dr Paul MacLeman||Executive ChairmanExecutive Director||May 2020||
Dr MacLeman has over 25 years' experience across all phases of the life sciences sector. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Dr MacLeman has experience in capital raising, business development, technology commercialization and sales & marketing globally. Dr MacLeman has launched products using both in-house and outsourced sales staff in Australia and the US. He has founded life sciences start-ups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Dr MacLeman has previously served as Chairman, Director or Managing Director/CEO of several VC funded, ASX, NASDAQ, CSE and TSX listed companies. Dr MacLeman is currently Executive Chairman of Isla Pharmaceuticals Inc., is Chairman of AdAlta Limited (1AD:ASX), Chairman of SuperTrans Medical Limited and non-executive director of Upkara Asia Pacific Pty Ltd. Dr MacLeman Chairs the Industry Review Committee for the Pharmaceutical Manufacturing National Training Package for the AISC. He is an expert advisor to PharmaVentures (Oxford, UK) and Mind Medicine. Dr MacLeman also serves on a number of other NFP and government advisory groups and has recently provided advice to both DESE and DISER related to Covid-19. He is also member of the Risk committee of the ILA.
|Dr David Lionel Brookes||Non-Executive Director||Oct 2020||
Dr Brookes has experience in the health and biotechnology industries, having been involved in the sector since the late 1990's, and maintaining roles as biotechnology industry consultant and as a clinician. Dr Brookes has held Board positions in a number of ASX listed biotechnology companies, including as Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc (NYSE:PKI) in June 2018. He is currently the Chair of ASX listed Factor Therapeutics Ltd. He is currently a non-executive director of ASX listed companies TALi Digital Ltd and Anatara Lifesciences Ltd and is the chair of the audit & Risk committee of both those companies. He is also Chair of the Risk committee of the ILA.
|Dr David Foster||Managing Director||Oct 2020||
Dr Foster has experience in the life science industry including 20+ years representing a range of companies, such as pharmaceutical, biotherapeutic and diagnostic companies while in private legal practice. In addition, he served as intellectual property counsel at Medarex, a mid-sized biotherapeutics company, acquired by Bristol-Myers Squibb. Dr Foster co-founded Roberts Foster LLP- a technology focused law firm, bionorthTx- a regional life science trade association, and multiple private biotechnology companies. He is a Board member of bionorthTx and private biotechnology companies. Dr Foster has experience in formulating intellectual property and business strategies to protect and develop therapeutic assets.
|Mr Albert Hansen||Non-Executive Director||Oct 2020||
Mr Hansen has over 25 years of private equity investment experience, with almost 20 years in the life sciences/pharmaceutical field. Mr Hansen is currently President of KESA Partners, Inc. (KESA) a family investment office focused on seed investing in life science-related startups. KESA provides capital and strategic management to its portfolio companies. Mr Hansen serves as President of one of KESA's portfolio companies, Clearlight Biotechnologies, Inc., which has licensed imaging technology for tissue analysis from Stanford University. From 2001 to 2012, Mr Hansen was a Managing Director of Signet Healthcare Partners, a growth capital private equity firm focused on emerging life science companies. He is a former Chairman and interim CEO of Questcor Pharmaceuticals, Inc, a former Chairman and interim CEO of Cedarburg Pharmaceuticals Inc. and former Chairman of Molecular Medicine Corporation. KESA Partners, Inc acquired a failing company, Bioserv Corporation, from NextPharma, Ltd in November 2012. He has also been a director of over ten other private companies. Prior to Signet, Mr Hansen was a principal of Darby Overseas, since acquired by Franklin Templeton. He was also a political appointee as Director of Corporate Finance at the U.S. Treasury Department in 1992. Earlier in his career, Mr Hansen was an investment banker with Dillon Read & Co. Inc., focusing on mergers and acquisitions. He was also an investment banker at E.F. Hutton & Co. Mr. Hansen also served in the U.S. Army as an Infantry and Special Forces officer.
|Dr Anna Lavelle||Non-Executive Director||Oct 2020||
Dr Lavelle is an experienced Non-Executive Director serving for over 25 years on the boards of not for profit, government and for profit entities. As Executive Director or Non-Executive Director she has gained experience in healthcare delivery, technology development and negotiating government policy. In 2015 Nature Scientific America, World View ranked Dr Lavelle in the global top 100 "World Visionaries" in biotechnology. Dr Lavelle was the only Australian to be named. From 2005 to 2016, Dr Lavelle was the CEO of AusBiotech; the national industry association for the biotechnology, pharmaceutical and medical devices sectors. Dr Lavelle is now serving on several boards including - Independent Chair, Medicines Australia Ltd, Independent Chair, Avatar Brokers Pty Ltd, Non-Executive Director Hemideina Pty Ltd, Non-Executive Director Cyban Pty Ltd. She is also a Fellow of the Leadership Victoria Program. He is also member of the Risk committee of the ILA.
|Mr Peter Webse||Company Secretary||
|Peter Webse||Company Secretary||
|Dr William James Garner||21,090,605||26.05%|
|Kesa Partners Inc||10,837,367||13.38%|
|CS Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C)||7,240,000||8.94%|
|Dr David C Foster||5,146,829||6.36%|
|Manchester Explorer Lp||3,774,139||4.66%|
|Mr Andre Fraga||2,312,947||2.86%|
|Jeb Partners Lp||1,993,861||2.46%|
|Sandhurst Trustees Ltd (Endeavor Asset Mgmt Mda A/C)||1,000,000||1.24%|
|Citicorp Nominees Pty Limited||940,000||1.16%|
|National Nominees Limited||800,000||0.99%|
|HSBC Custody Nominees (Australia) Limited||740,000||0.91%|
|Altor Capital Management Pty Ltd (Altor Alpha Fund A/C)||720,000||0.89%|
|Mr Richard M Hemry||679,340||0.84%|
|Ms Patricia Dias Almeida||660,861||0.82%|
|Sandhurst Trustees Ltd (Wunala Capital A/C)||660,000||0.82%|
|UBS Nominees Pty Ltd||600,000||0.74%|
|Dr Daniel Tillett||495,918||0.61%|
|Pac Partners Securities Pty Ltd||440,000||0.54%|
|Gor Zhirar Karapetyan||407,604||0.50%|
|Mr James Besser||377,441||0.47%|
|Mr Morgan Frank||377,441||0.47%|